Skip to main content

HE4 combined with CA125: favorable screening tool for ovarian cancer

Medical Oncology volume 31, Article number: 808 (2014) Cite this article

Abstract

Ovarian cancer is one of the most prevalent malignancies in women. Screening of the disease is done using variety of biomarkers. Diagnostic performance of current biomarkers of the disease such as human epididymis protein (HE4) and CA125 shows contradiction in previous studies. The goal of this study was to evaluate serum levels of CA125 and HE4 in Iranian patients with ovarian cancer and compare specificity and sensitivity of HE4, CA125 and HE4 + CA125 in patients with different stages and diverse histology. To evaluate CA125 and HE4, 32 patients and 34 healthy women were selected. Origin of ovarian cancer was verified by expert gynecological oncologist. Significance and diagnostic performance were determined by ANOVA and receiver operator characteristic (ROC) and areas under the curve (AUC), respectively. Serum levels of CA125 and HE4 were significantly increased in patients in comparison with control group, especially for tumor cells originated from epithelium (p < 0.001). ROC–AUC for HE4, CA125 and HE4 + CA125 were 0.91, 0.86 and 0.91, respectively. Specificity of HE4 was more than CA125 (85 vs. 80 %). Conversely, sensitivity of CA125 was higher in comparison with HE4 (90 vs. 80 %). It is being noticed that cutoff point of HE4 and CA125 was 150 pmol/L and 38 U/mL, respectively. HE4 is slightly more specific for diagnosis of early stages of the disease, but the difference is not remarkable. CA125 and HE4 + CA125 have some diagnostic performance for prediction of advanced stages. Generally, the data of present study suggest that combining of HE4 and CA125 is a better screening tool for diagnosis of ovarian cancer.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.

    PubMed  Article  Google Scholar 

  2. Menon U, Jacobs I. Ovarian cancer screening in the general population: current status. Int J Gynecol Cancer. 2001;11(s1):3–6.

    PubMed  Article  Google Scholar 

  3. Bast RC. Status of tumor markers in ovarian cancer screening. J Clin Oncol. 2003;21(10 suppl):200s–5s.

    PubMed  Article  Google Scholar 

  4. Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, et al. Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol. 2010;116(3):378–83.

    PubMed Central  PubMed  Article  Google Scholar 

  5. Rauh-Hain JA, Krivak TC, del Carmen MG, Olawaiye AB. Ovarian cancer screening and early detection in the general population. Rev Obstet Gynecol. 2011;4(1):15.

    PubMed Central  PubMed  Google Scholar 

  6. Zurawski VR Jr, Knapp RC, Einhorn N, Kenemans P, Mortel R, Ohmi K, et al. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol. 1988;30(1):7–14.

    PubMed  Article  Google Scholar 

  7. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10(4):327–40.

    PubMed  Article  Google Scholar 

  8. van Nagell JR, DePriest PD, Ueland FR, DeSimone CP, Cooper AL, McDonald JM, et al. Ovarian cancer screening with annual transvaginal sonography. Cancer. 2007;109(9):1887–96.

    PubMed  Article  Google Scholar 

  9. Galgano MT, Hampton GM, Frierson HF. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19(6):847–53.

    CAS  PubMed  Google Scholar 

  10. Nagy B, Krasznai ZT, Balla H, Csobán M, Antal-Szalmás P, Hernádi Z, et al. Elevated human epididymis protein 4 concentrations in chronic kidney disease. Ann Clin Biochem. 2012;49(4):377–80.

    CAS  PubMed  Article  Google Scholar 

  11. Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63(13):3695–700.

    PubMed  Google Scholar 

  12. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112(1):40–6.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  13. Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA, Ghaffar HMA. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Diagn Pathol. 2013;8(1):11.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  14. Partheen K, Kristjansdottir B, Sundfeldt K. Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass. J Gynecol Oncol. 2011;22(4):244–52.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  15. Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer. 2011;104(5):863–70.

    PubMed Central  PubMed  Article  Google Scholar 

  16. Anastasi E, Granato T, Falzarano R, Storelli P, Ticino A, Frati L, et al. The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer. J Ovarian Res. 2013;6(1):44.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  17. Park Y, Lee J-H, Hong DJ, Lee EY, Kim H-S. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem. 2011;44(10):884–8.

    CAS  PubMed  Article  Google Scholar 

  18. Bingle L, Cross SS, High AS, Wallace WA, Rassl D, Yuan G, et al. WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res. 2006;7(1):61–70.

    PubMed Central  PubMed  Article  Google Scholar 

  19. Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet. 1999;353(9160):1207–10.

    CAS  PubMed  Article  Google Scholar 

Download references

Acknowledgments

This study was supported by Yazd Clinical and Research Center for Infertility Shahid Sadoughi.

Conflict of interest

No conflict of interest declared.

Author information

Affiliations

  1. Yazd Clinical and Research Center for Infertility, Shahid Sadoughi Medical University, Yazd, Yazd, Iran

    Nasrin Ghasemi, Samira Ghobadzadeh, Mahnaz Zahraei, Mohammad Bakhshi ganje & Shokoh Rajabi

  2. Department of Medical Immunology, Faculty of Medical Science, Tarbiat Modares University, Tehran, Iran

    Samira Ghobadzadeh & Hemn Mohammadpour

  3. Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran

    Salahadin Bahrami

Authors
  1. Nasrin Ghasemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samira Ghobadzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mahnaz Zahraei
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hemn Mohammadpour
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Salahadin Bahrami
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mohammad Bakhshi ganje
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shokoh Rajabi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hemn Mohammadpour.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ghasemi, N., Ghobadzadeh, S., Zahraei, M. et al. HE4 combined with CA125: favorable screening tool for ovarian cancer. Med Oncol 31, 808 (2014). https://doi.org/10.1007/s12032-013-0808-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-013-0808-0

Keywords

  • Ovarian cancer
  • HE4
  • CA125
  • Tumor marker
  • Risk of ovarian malignancy